Krystal Biotech (NASDAQ:KRYS) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Krystal Biotech (NASDAQ:KRYS) released its earnings results on Monday. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03, Briefing.com reports. The company had revenue of $70.28 million for the quarter, compared to analysts’ expectations of $65.27 million. Krystal Biotech’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same quarter last year, the firm posted ($1.25) earnings per share.

Krystal Biotech Trading Down 0.6 %

KRYS traded down $1.16 on Wednesday, hitting $177.45. The company had a trading volume of 162,392 shares, compared to its average volume of 380,467. The firm has a market cap of $5.07 billion, a P/E ratio of 95.51 and a beta of 0.84. The company’s fifty day moving average price is $185.89 and its 200 day moving average price is $164.54. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34.

Insiders Place Their Bets

In other Krystal Biotech news, Director Julian S. Gangolli sold 20,000 shares of the business’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $164.13, for a total transaction of $3,282,600.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now owns 1,525,882 shares of the company’s stock, valued at $268,189,020.32. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Julian S. Gangolli sold 20,000 shares of Krystal Biotech stock in a transaction on Monday, May 20th. The stock was sold at an average price of $164.13, for a total value of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KRYS shares. Chardan Capital increased their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday. Citigroup restated a “neutral” rating and issued a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a report on Tuesday. Stifel Nicolaus restated a “buy” rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Finally, HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Krystal Biotech in a report on Monday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $185.63.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).